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Objectives: To investigate the frequency of Human papillomavirus (HPV)-driven head and neck squa-
mous cell carcinoma (HNSCC) among patients living in North-East Italy, by assessing HPV-DNA positivity
in all tumors and additional markers whenever possible.
Material and methods: HPV types, viral load, viral RNA, HPV16/18 E6 protein and p16INK4a and pRb ex-
pression were determined in primary tumor tissues from 247 HNSCC patients. Tumor-speciﬁc HPV ser-
opositivity was analyzed in 102 patients.
Results: Tumor HPV-DNA prevalence was 8.5% overall (21/247) and 27% in oropharynx (17/63). HPV16
accounted for 95% of all HPV types found. Among HPV-DNAþ tumors, type-concordant HPV E6*I RNA
prevalence was 79%. HPV DNAþ RNAþ tumors showed high viral load, up-regulated p16INK4a, down-
regulated pRb and presence of HPV16 E6 protein. Eight cases showed tumor-speciﬁc HPV seropositivity,
all type-concordant with the tumor. Tumors were deﬁned as HPV-driven when positive for HPV-DNA
plus 2 additional HPV transformation-related markers.
Conclusion: Relative prevalence of HPV-driven tumors (14 HPV16, 1 HPV58) was 6% overall and 20%
among oropharyngeal cancers. In the oropharynx the HPV-driven group showed a trend for better
survival versus the HPV-negative group.
The relative prevalence of HPV-driven oropharyngeal cancer is low in North-East Italy as compared to
Western and Northern Europe.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).B.V. This is an open access article u
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Head and neck squamous cell carcinoma (HNSCC) accounts for
approximately 5% of all cancers worldwide [1]. Globally, human
papillomavirus (HPV) DNA was found in 30% of HNSCC, with a
higher prevalence in oropharyngeal SCC (OPSCC) (46%) than oral
SCC (24%) or laryngeal and hypopharyngeal SCC (22%) [2].
Among the 12 HPV types (HPV16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58 and 59) deﬁned as carcinogenic in cervical carcinoma
(CxCa) by the International Agency for Research on Cancer (IARC),
only type 16 is currently recognized as carcinogenic in OPSCC [3].
A wide variation of HPV DNA prevalence in OPSCC has been
reported in the literature between regions and countries and
within regions and countries, with overall ﬁgures higher in Northnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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for Northern to 24.2% for Southern countries within Europe [2].
While in the last decades HNSCC showed declining or un-
changed incidence, an increase of HPV-associated HNSCC, parti-
cularly for the oropharynx, was observed [4]. In countries like USA,
Denmark, Norway and Spain a 5% yearly increase (not statistically
signiﬁcant in Spain) of new OPSCC or tonsillar carcinoma cases
was reported [5–8]. In other surveys the increase was not observed
[9], while for several areas data are still scarce.
However, only a subset of HPV DNA positive HNSCC display
HPV carcinogenic activity in the tumor tissue, i.e. are HPV-driven.
Thus, the presence of HPV DNA alone is not a sufﬁcient proof for
causal involvement of HPV in HNSCC tissue [10]. The HPV carci-
nogenic model derived from CxCa [11] was also recently conﬁrmed
for OPSCC [12].
Truly HPV-driven tumor cells contain at least one viral genome
copy per cell and express the viral oncogenes E6 and E7 [11]. In-
teraction of the viral E7 and E6 proteins with key regulators of cell
cycle and apoptosis leads to up-regulation of cellular protein
p16INK4a [13] and down-regulation of tumor suppressor proteins
pRb and p53. Patients with invasive HPV-driven cervical [14], pe-
nile [15] and oropharyngeal [16] SCC frequently show strong an-
tibody responses against HPV E6 and E7 proteins while such an-
tibodies are rare in tumor-free populations. Clinically, patients
with HPV DNA positive HNSCC in comparison to those with HPV
DNA negative HNSCC present a smaller tumor size, early nodal
involvement, and are more frequently nonsmokers and non drin-
kers [17]. Controversial data were reported regarding younger age
of HPV-positive HNSCC patients [18].
In Italy, HNSCC accounts for approximately 5% of all cancers
[19]. The prevalence of HPV-DNA positive HNSCC cases reported so
far has ranged from 10% [20] to 46% [21]. Most of the studies relied
on qualitative HPV DNA markers alone, only a few included de-
tection of viral transcripts [20,22,23] or the expression of the
p16INK4a protein [24,25].
In the present study, we provide new data on prevalence of
HPV-driven HNSCC in North-East Italy, evaluate their clinical
outcome and suggest a combination of markers to deﬁne the HPV-
driven cases.2. Patients and methods
2.1. Patients and samples
A total of 247 patients diagnosed with primary HNSCC located
in oral cavity (International Classiﬁcation of Diseases for Oncology
(ICD-O): C02–04, C05.0, C06), oropharynx (ICD-O: C01, C05.1,
C05.2, C09, C10), larynx (ICD-O: C32, C10.1) and hypopharynx
(ICD-O C12–13) from 2003 to 2012 in the ENT (Ear Nose and
Throat) Units of Treviso Regional Hospital, Hospital of Mirano and
Hospital of Cattinara (Trieste), North-East Italy, were enrolled in
the study. The ﬁrst 77 enrolled patients have been already re-
ported [20]. The whole study was approved by the ethic com-
mittee for clinical experimentation (CEP) of Treviso (Ethic votes:
345/AULSS9 and 421/AULSS9). All patients signed an informed
consent.
Of the enrolled patients, 75% were males, 36% never tobacco
smokers and 30% never alcohol drinkers. Of the tumors, 39% were
in the larynx, 26% each in the oropharynx and the oral cavity and
10% in the hypopharynx. Small-sized T category (T1-T2) was pre-
sent in 50% of the patients, with regional lymph nodes being in-
volved in 52%. Only 1% of patients had distant metastases at di-
agnosis date.
From all the enrolled patients we obtained fresh frozen (FF)
specimens of the neoplastic lesions. Formalin-ﬁxed parafﬁn-embedded (FFPE) tumor tissues of 54 (22%) cases were retrieved
from one of the three participating centres (Treviso), and used to
complete molecular analyses of HPV-DNA-positive cases with
small FF samples, and to perform immunohistochemistry. Sera
were collected starting in 2010 from a total of 102 (41%) patients.
Anatomical and clinical data were collected and available from the
clinical database for each patient. No differences were observed
between the above-mentioned subgroups and the whole case
series. Histological diagnoses were determined by the local pa-
thologists. Management decisions for the patients were not guided
by knowledge of HPV status or other tested markers.
2.2. Tissues sectioning and DNA analyses
HPV analyses were carried out partly at the Veneto Institute of
Oncology and partly at the German Cancer Research Center;
homogenization in liquid nitrogen of the cryosections [26] was
performed only in the German Center. The mean tumor content on
adjacent hematoxylin-and-eosin stained sections was 55% (range
25–80%).
DNA was isolated from all 247 FF tumor tissues by Phenol-
Chlorophorm (PC9) method as described in [27,28]. One-hundred-
fourteen samples were re-sectioned and DNA was re-extracted by
MagNA Pure 96 DNA and viral NA Large Volume Kit (Roche,
Penzberg, Germany) according to the manufacturer´s re-
commendations [26,29].
FFPE sectioning and genomic DNA extraction were performed
as described in [29].
PC9-extracted DNA was tested by MY09/MY11 PCR and re-
striction fragment length polymorphism (RFLP) analysis of the
ampliﬁcation products [30].
MagNA Pure-extracted DNAwas analyzed by BSGP5þ/6þ-PCR/
MPG51 assay, a broad-spectrum PCR for 51 mucosal HPV types
followed by hybridization to type-speciﬁc probes on Luminex
beads [31,32].
DNA quality of samples tested by MY09/MY11 was veriﬁed by
ampliﬁcation of the β-globin gene; the analytical sensitivity ranges
from 102 to 104 HPV copies for any of the 49 HPV mucosal types
[33]. All samples were also analyzed by HPV16 type-speciﬁc PCR
[20].
The analytical sensitivity for any of the 51 HPV types detected
by the BSGP5þ/6þ-PCR/MPG51 assay is equal or less than 100
viral genome copies [29].
HPV16 viral loads were determined by quantitative (q)PCR
targeting E6 gene sequences (Schmitt et al. submitted) and ex-
pressed as HPV16 genome copy-number per cell. A cut-off of
0.1 copies per cell deﬁned high (HPV16highZ0.1) or low
(HPV16lowo0.1) viral load. Real-time qPCR for β-globin was used
to verify the DNA quality and to measure the amount of input DNA.
The analytical sensitivity for both HPV16 and β-globin detection is
below 100 plasmid copies.
HPV58 viral load was estimated from the quantitative BSGP5þ/
6þ- PCR/MPG51 data as described in [32].
2.3. RNA isolation and E6*I mRNA reverse transcription (RT)-PCR
RNA was isolated from FF sections using the RNeasy Mini kit
(Qiagen, Hilden, Germany) and from FFPE sections using the Pure
Link FFPE Total RNA Isolation Kit (Invitrogen, Carlsbad, CA). DNase
I digestion (RNase-free DNase Set, Qiagen) was included to ensure
an exclusive ampliﬁcation of RNA, and was carried out on the RNA
purifying columns during sample processing.
All samples HPV DNA positive by either method and a group of
HPV DNA negatives were analyzed for ubiquitin C and HPV16 E6*I
RNA and for E6*I RNA of additional HPV types positive by HPV
genotyping [29].
Table 1
Clinicopathologic characteristics of the 247 study participants stratiﬁed by HPV
DNA and by HPV-driven status.
Total HPVDNA_ HPVDNAþ HPV-
driven
Characteristicsa N¼247 N¼226 N¼21 N¼15/19
tested
Age (Median, y) 65 65 68 68
N (%) N (%) N (%) N (%)
Gender Male 188 (76) 173 (76) 15 (71) 9 (60)
Female 59 (24) 53 (24) 6 (29) 6 (40)
Tobaccob Never 79 (32) 69 (31) 10 (48) 8 (53)
Former 34 (15) 30 (13) 4 (19) 3 (20)
Current 124 (50) 118 (52) 6 (28) 3 (20)
Missing 10 (4) 9 (4) 1 (5) 1 (7)
Alcoholb Never 75 (30) 69 (31) 6 (28) 5 (33)
Former 29 (12) 26 (11) 3 (14) 1 (7)
Current 131 (53) 120 (53) 11 (53) 8 (53)
Missing 12 (5) 11 (5) 1 (5) 1 (7)
Localization Oral cavity 63 (26) 62 (28) 1 (5) 1 (7)
Oropharynx 63 (26) 46 (20) 17 (81) 13 (86)
Larynx 96 (39) 95 (42) 1 (5) 1 (7)
Hypopharynx 25 (9) 23 (10) 2 (9) 0
Tumor size T1-T2 124 (50) 113 (50) 11 (52) 8 (53)
T3-T4 123 (50) 113 (50) 10 (48) 7 (47)
Lymph nodes N0 128 (52) 123 (54) 5 (24) 4 (27)
Nþ 119 (48) 103 (46) 16 (76) 11 (73)
Metastasis M0 244 (99) 223 (99) 21 (100) 15 (100)
Mþ 3 (1) 3 (1) 0 0
a P-value (by chi-square analyses) referred to the HPV-DNAþ and HPV-DNA-
groups was statistically signiﬁcant (0.0001) only for oropharyngeal localization.
b For statistical analyses, tobacco and alcohol categories were simpliﬁed in
never and current (which includes current and former) tobacco/alcohol consumers.
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Immunostaining was performed on FFPE sections to evaluate
the expression of the HPV-targeted cellular proteins p16INK4a and
pRb, as previously described in detail [12]. p16INK4a protein was
detected using the primary antibody CINtec for V-kit (MTM la-
boratories, Heidelberg, Germany) while pRb protein was detected
using the NCL-RB (Novocastra, Newcastle upon Tyne, United
Kingdom) antibody. Stained sections were evaluated by two in-
vestigators (L.B. and D.H.), applying two protein expression cate-
gories, low and high. The cut-off for protein up- or down-regula-
tion was determined by evaluation of the staining intensity and
stain distribution in sections of healthy uvula (nuclear and cyto-
plasmic signal absent for p16INK4a and abundant for pRb) analyzed
in parallel with cervical carcinoma tissues (nuclear and cyto-
plasmic signal present for p16INK4a and o25% for pRb). For in-
itially discordant cases a consensus was reached after joined re-
view and discussion.
2.5. Multiplex serology
The presence of HPV antibodies against the E6 and E7 proteins
of high-risk HPV types 16, 18, 31, 33, 45, 52 and 58 and low-risk
types 6 and 11 was investigated by multiplex serology (MS), a
glutathione S-transferase (GST) capture immunosorbent-based
assay combined with ﬂuorescent bead technology as previously
described [34].
2.6. HPV16 E6 protein detection
E6 protein of HPV16 and HPV18 was analyzed in lysates ob-
tained from FF tumor sections by the OncoE6™ test (Arbor Vita
Corporation, Fremont) following the manufacturer's instructions
[35]. The assay is an immunographic assay which consists in the
capture of the E6 protein with monoclonal antibodies and its de-
tection through colorimetric visualization. The analytical sensi-
tivity of the assay, as determined in 10-fold dilution series of the
HPV16 positive cervical carcinoma cell line MRI-H 186, was less
than 5103 cells (Holzinger et al., manuscript in preparation).
2.7. Statistical analyses
Patient and tumor characteristics were evaluated in relation to
the HPV DNA status. Follow-up was determined as the time-dif-
ference between the date of primary tumor diagnosis and the last
clinical examination.
Overall survival (OS) was determined as time interval from date
of diagnosis until date of death (by any cause). Progression-free
survival (PFS) time was determined as time interval from the date
of primary tumor diagnosis to the date of the ﬁrst negative event
(local or regional recurrence, metastasis, second primary HNSCC)
or death from any cause.
The Kaplan-Meier method was used to estimate survival dis-
tributions. Patients with HPV-driven and HPV non-driven tumors
were compared using the log-rank test. In all statistical tests a P
value of 0.05 or below was considered as statistically signiﬁcant.
The statistical analyses were carried out using SAS as well as the
Sigmaplot softwares.3. Results
The anatomo-clinical characteristics of the 247 HNSCC enrolled
patients (age range 27–95 years) are described in Table 1. The main
results for HPV-DNA, HPV-RNA and p16 IHC are illustrated in Fig. 1.3.1. Human papillomavirus DNA and RNA prevalence
All DNA samples extracted from FF and FFPE tissues were β-
globin positive in the genotyping assays and thus valid for HPV
DNA analyses. All the 247 DNA samples were tested by MY09/
MY11 PCR-RFLP, and 114 were additionally tested by BSGP5þ/6þ
PCR/MPG51. Agreement between the two methods calculated for
the latter group resulted in a k-value of 0.8 (good agreement).
HPV DNA prevalence was 8.5% (21/247) (Fig. 2). HPV type 16
accounted for 95% (20/21) of HPV DNA positive cases, and HPV58
was identiﬁed once (5%). No multiple infections were identiﬁed.
HPV DNA prevalence was highest in the oropharynx (27%, 17/
63) (Po0.0001) and low in hypopharynx (8%, 1/25), oral cavity
(2%, 1/63) and larynx (1%, 1/96).
A total of 45 RNA samples from 18 HPV DNA positive (17 for
HPV16 and 1 for HPV58) and 27 HPV DNA negative cases were
prepared for HPV16 E6*I and ubiquitin C RNA analyses. Of 3 HPV
DNA positive cases (2 oropharynx, 1 larynx) no sufﬁcient tumor
sample was available for RNA extraction. All RNA samples were
valid (ubiquitin C RNA positive). All 27 HPV DNA negative tumors
analyzed showed no presence of HPV16 transcripts.
Among the 17 HPV16 DNA positive samples, 4 were HPV16 RNA
negative and 13 showed expression of type-concordant HPV16
E6*I RNA; the single case identiﬁed as HPV58 DNA positive
showed presence of HPV58 E6*I transcripts and absence for HPV16
E6*I transcripts (Fig. 2). Therefore, 14/18 (77.8%) HPV-DNA-positive
samples were also RNA-positive.
Compared to the other head and neck anatomical sites, the
oropharynx with a ﬁgure of 20% (12/61) showed the highest pre-
valence of HPV DNA and RNA positive tumors, followed by 1.6% (1/
63) in the oral cavity, 1% (1/94) in the larynx, and 0% (0/25) in the
hypopharynx.
Fig. 1. Flow chart of the most signiﬁcant analyses (i.e. E6*I mRNA RT-PCR,HPV viral load by HPV16 ultrashort-qPCR or MPG MFI, and p16 IHC) performed on the tumors of the
247 HNSCC enrolled patients, by HPV-DNA status. 138/247 (56%) samples were double tested for HPV-DNA by BSGP5þ/6þ-PCR/MPG51 (MPG) and MY09/MY11-RFLP (MY),
and 109/247 (44%) by MY only. HPVþþ and HPV: sample positive or negative by both methods; HPVþ and HPV: sample positive or negative by one method only.
HPVþ and HPVþ: sample positive/negative or negative/positive by MPG and MY, respectively. Overall, 3 cases were discordant (2 HPVþ and 1 HPVþ); considering
that the MPG sensitivity is higher compared to the MY assay, the 2 HPVþ and 1 HPVþ were considered as positive and negative, respectively. HPV16high: 40.1 HPV16
copies per cell; HPV16low: o0.1 HPV16 copies per cell. p16 high: nuclear and cytoplasmic signal present in most tumor cells.
Fig. 2. Overall and site speciﬁc HPV DNA and RNA prevalence among all head and
neck tumors and stratiﬁed by anatomical site. Overall, 247 tumors were analyzed
for HPV DNA, 63 from the oropharynx, 63 from the oral cavity, 96 from the larynx,
and 25 from the hypopharynx. Of the 21 HPVDNA positive tumors, 18 were ana-
lyzed for HPV RNA, while 3 (2 from oropharynx and 1 from larynx) could not be
analyzed.
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3.2.1. HPV16 viral load
One out of 18 HPV DNA positive samples was β-globin DNA
negative (invalid). A high viral load (40.1 HPV16 genome copies/
tumor cell and/or high MPG MFI) was present in 82% (14/17) of
HPV DNA positive valid samples (median ¼33.7 HPV16 genome
copies per cell, range 0.6–1000). The other 3 carcinomas contained
o0.002 HPV genome copies/tumor cell. All the HPV RNA positive
tumors had a high viral load. One HPV16 high viral load tumor (Nr.
16) was HPV RNA negative and showed no p16INK4a up-regulation
nor pRb down-regulation.
3.2.2. p16INK4a and pRb expression
Of the 54 tumors stained for p16INK4a, 2 were excluded (1 case
not evaluable for tumor section loss during staining and no addi-
tional material available, and the other for lack of tumor cells in
the stained section). Out of 11 HPV DNA positive tumors with valid
results analyzed, p16INK4a up-regulation was recorded in 9, all HPV
RNA positives, while the 2 HPV RNA negatives were p16-negative.
Among the 41 HPV DNA negative tumors, one case showed
p16INK4a up-regulation.
pRb expression was analyzed in 48 cases; 1 case was excluded
due to lack of tumor cells in the stained section. Of the 10 HPV
L. Baboci et al. / Papillomavirus Research 2 (2016) 133–140 137DNA and RNA positive tumors, only 6 showed pRb down-regula-
tion. No pRb down-regulation was observed in the HPV DNA po-
sitive RNA negative tumor and in 35 of 36 HPV DNA negative
tumors.
3.2.3. HPV16 E6 protein expression
HPV16 E6 protein was detected in lysates of 7/7 analyzed tu-
mors positive for high viral load HPV16 DNA and for E6*I RNA. Two
low viral load HPV16 DNA positive but HPV16 RNA negative tu-
mors showed no HPV16 E6 protein.
3.2.4. HPV antibodies
All the 7 HPV DNA and HPV RNA positive tumors analyzed by
serology showed antibodies to both HPV E6 and E7 proteins of the
tumor-infecting HPV type. Anti-E6 and -E7 double seropositivity
was also observed in one additional case with HPV16 DNA positive
tumor for which the other tissue markers could not be analyzed
and among 92 HPV DNA negative tumors.3.3. Deﬁnition of HPV-driven HNSCC
The full spectrum of HPV transformation-associated markers
analyzed includes high viral load, HPV RNA expression, p16INK4a
up-regulation, pRb down-regulation, HPV E6 protein and ser-
opositivity to HPV E6 and E7 of the tumor infecting HPV type
(Table 2). Cases were deﬁned as HPV-driven when positive for HPV
DNA and at least 2 additional HPV transformation-associated
markers.
Due to limited tissue availability, 2 out of 21 HPV DNA positive
cases could not be further analyzed and therefore could not be
deﬁned.
Of 19 HPV DNA positive tumors analyzed for additional HPV
transformation markers, 15 (79%) were HPV-driven and 4 non-
HPV-driven.Table 2
Deﬁnition of HPV-driven HNSCC. From left: anatomic site, HPV types identiﬁed, HPV ty
down-regulation, antibodies to HPV16 and HPV58 E6 and E7 proteins, HPV16 E6 protein,
bold.
Nr. Anatomic site HPV type Viral load p16INK4a up-regulation p
DNAþ RNAþ
1 Oropharynx 16 16 1.3
2 Oropharynx 16 16 1000 n
3 Oropharynx 16 16 26 yes y
4 Oropharynx 16 16 24 yes n
5 Oropharynx 16 16 40
6 Oropharynx 16 16 3 yes n
7 Oropharynx 16 16 36 yes y
8 Larynx 16 16 25 yes y
9 Oropharynx 16 16 285 yes y
10 Oropharynx 16 16 145 yes n
11 Oropharynx 16 16 0.6
12 Oropharynx 16 16 37
13 Oropharynx 58 58 higha yes y
14 Oral cavity 16 16 invalid yes y
15 Oropharynx 16
16 Hypopharynx 16 no 208 no n
17 Oropharynx 16 no o0.001
18 Hypopharynx 16 no o0.001
19 Oropharynx 16 no o0.001 no
20b Oropharynx 16
21b Oropharynx 16
a High¼tested by quantitative BSGP5þ/6þ-PCR MPG51 assay [32]; empty¼sample
b Tumor cases 20 and 21 are not deﬁned since no additional HPV transformation-a3.4. Patients’ survival after HNSCC diagnosis
The cut-off date for follow-up was June 30, 2013 and follow-up
time was 1–121 months (median 20 months).
Of the 247 patients, 152 (61.5%) were alive at time of analysis;
death had occurred in overall 95 (38.5%) patients, in 53 due to the
primary tumor, in 20 due to a second malignancy, while in 22 was
not tumor-related. A negative event (local, regional or distant re-
current HNSCC or second primary tumor) was recorded for 93
(37.7%) patients. Overall, a difference in clinical outcome was re-
corded between patients with HPV-driven and HPV-non driven
tumors (statistically not signiﬁcant, data not shown). Restricting
the analyses to the oropharynx site (i.e., 61 cases on which HPV
causality was assessed), a trend of better survival (OS and PFS,
statistically signiﬁcant for PFS) was observed in patients with HPV-
driven tumors (13 cases) compared to the group (48 cases) with
HPV non-driven tumors (Fig. 3, A and B).4. Discussion
We enrolled 247 patients with primary HNSCC and analyzed
the neoplastic tissue of all cases for HPV DNA. All available HPV
DNA positive tumors and a randomly selected group of HPV DNA
negative tumors were further tested for presence of HPV-trans-
formation-associated markers, i.e. high viral load, HPV RNA ex-
pression, p16INK4a up-regulation, pRb down-regulation, HPV E6
protein, and seropositivity to HPVE6 and E7 of the tumor infecting
HPV type.
The overall HPV DNA prevalence was low for all HNSCC and
also among the oropharyngeal cancers (8.5% and 27%, respectively)
compared to the reported global HPV DNA prevalences (30% and
46%, respectively) [2], but similar to the rates for HNSCC reported
in Spain (6%) [8] and France (13%) [36].
HPV prevalence among patients with HNSCC in Italy was ana-
lyzed in a low number of studies, that reported a highly variable
range (from 10% [20] to 46% (by nested PCR) [21]).pe of E6*I RNA, viral load by HPV16 qPCR (copies/cell), p16INK4a up-regulation, pRb
ﬁnal HPV status. Positivity for individual HPV transformation markers highlighted in
Rb down-regulation HPV16/58 HPV16 E6 protein HPV-driven
Ab E6þ Ab E7þ
yes yes
o yes
es yes
o yes yes
yes yes
o yes
es yes yes yes yes
es yes yes yes yes
es yes yes yes
o yes yes yes
yes yes yes yes
yes yes yes yes
es yes yes yes yes
es yes
yes yes yes
o no
no no
no no
no
n.d
n.d
not tested; Ab¼antibody; n.d¼not deﬁned.
ssociated data could be obtained.
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probably due to the actual main role of tobacco smoking and al-
cohol consumption in this area [37,38], where programmes for
tobacco use and alcohol abuse prevention have been less efﬁcient
than in Northern America and Northern Europe. In fact, in our
series most (460%) of the patients were current tobacco smokers
and/or alcohol drinkers. In relation to these risk factors, we could
see a signiﬁcantly higher prevalence of HPV in never tobacco
smokers (12.4% (14/113) vs 4.8% (6/124); Po0.05) but not in never
alcohol drinkers (P40.05) (data not shown). A study conducted in
Germany [39] showed a similar proportion of smokers and a 40%
HPV prevalence among OPSCC, with a statistically signiﬁcant
higher HPV prevalence among never/ex-smokers compared to
current smokers.
With 93%, HPV16 was identiﬁed as the most prevalent type in
HPV-driven HNSCC in contrast to CxCa in which HPV16 con-
tributes to about 60% of the HPV-driven tumors, with other HPV
types such as 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59 driving the
remaining CxCa [2,29]. In our case series, we identiﬁed one case
with HPV58 as single type infection and could demonstrate its
causal involvement by a broad variety of viral and cellular markers,
as described in detail previously [40].
The presence of HPV DNA alone is not sufﬁcient to determine
causality in HNSCC. For cervical carcinoma [29], and recently for
oropharyngeal [16] and laryngeal cancer [41], several markers,
used alone or combined, were established as stringent criteria to
discriminate HPV-driven from HPV non-driven cases. For HNSCC
in Italy, the analysis of HPV prevalence by using at least one ad-
ditional HPV transformation-speciﬁc marker is reported only in a
few studies [20,22].
The most accurate marker to demonstrate viral activity and the
transforming capability of HPV in the tissues is considered to be
the detection of viral mRNA encoding the two viral oncoproteins
E6 and E7 [26].
RNA of sufﬁcient quality is often difﬁcult to obtain especially
when no fresh frozen material is available. We could use an ultra-
short E6*I RNA assay adequate to successfully analyze also FFPE
specimens. To increase transformation-speciﬁcity, in addition to
RNA analysis, we analyzed several HPV-transformation speciﬁc
(direct and/or indirect) markers that allowed us to robustly dis-
criminate HPV-driven from HPV non-driven tumors, and allowed
for rare technical failures of one method in individual cases. De-
pending on the availability of the sample, we could not further
analyze two HPV DNA positive samples.
We deﬁned as HPV-driven only tumors positive for HPV DNA
and at least 2 additional HPV-transformation associated markers.
With such cut-off, 79% of DNA positive tumors were conﬁrmed as
HPV-driven [2,26].
In line with the literature [26], we observed a good con-
cordance between presence of viral transcripts and high viral load
(at the cut-off of 0.1 HPV genome copies per tumor cell) and with
detection of the newly introduced marker E6 protein (93% and
100%, respectively).
E6 protein could represent a good marker to identify HPV-
driven carcinomas. Although we could test the presence of the E6
protein only in a limited number (9) of cases, we observed a 100%
concordance with HPV RNA positivity. In a larger set of HPV-driven
and HPV non-driven HPV16 DNA positive OPSCC (Holzinger et al.,
manuscript in preparation), sensitivity and speciﬁcity of HPV16 E6
detection to classify HPV16-driven OPSCC was 97% and 96%, re-
spectively, showing an excellent agreement with the HPV RNA
status (κ¼0.94).
Expression of HPV E6 oncoprotein reduces the steady state
level of p53 that induces upregulation of p16INK4a protein ex-
pression via a negative feedback mechanism. Conversely, expres-
sion of the HPV E7 protein leads to pRb degradation. Therefore, inHPV-driven OPSCC p16INK4a is almost always up-regulated while
pRb is frequently albeit not always down-regulated, making these
2 proteins of potential use as indirect markers [12].
In our series, p16INK4a protein showed a higher sensitivity
(100%) but a lower speciﬁcity (75%) compared to pRb protein (60%
and 97.3%, respectively) [42]. Comparing up-regulation of p16INK4a
and down-regulation of pRb (as single markers) with HPV RNA
positivity, we had a concordance of 100% and 60%, respectively.
p16INK4a protein is considered to be a reliable surrogate marker in
CxCa [43], and other HPV-associated anogenital cancers [44]. In
HNSCC, p16INK4a was a more reliable marker in tumors arising
from the oropharynx [10,45] and larynx [41] than in hypophar-
yngeal [46] and oral cavity carcinoma [47]. Nevertheless, a fraction
of oropharyngeal tumors have up-regulated p16INK4a but lack HPV
DNA positivity, and are similar to the non-HPV associated or-
opharyngeal tumors [48]. In our study we could not test all the
HPV-negative samples, so we cannot afﬁrm that all the HPV-ne-
gative tumors were also p16 negative.
HPV type concordant E6 and E7 double antibody positivity has
been demonstrated to be highly associated and speciﬁc for in-
vasive HPV-associated cancers with an extremely low prevalence
of about 0.1% in tumor-free individuals [16] and to be strongly
associated (odds ratios of 44-180) with invasive cancer of the
cervix [14], the penis [15] and the upper aerodigestive tract [16].
Interestingly, among the 102 patients for whom anti-HPV anti-
bodies could be assessed, the sera from all the 7 patients with HPV
RNA positive tumors showed strong positive antibody responses
against both type-concordant HPVE6 and E7 proteins. In contrast,
none of the sera from 92 patients with HPV DNA negative tumors
reacted positive with both E6 and E7 for any of the 7 high-risk and
2 low-risk HPV types tested. In this study, double HPVE6 and E7
seropositivity was the best marker to identify the type concordant
HPV RNA positive cases in the tumor, with a 100% sensitivity and
100% speciﬁcity.
Based on the correlations found for each of the analyzed mar-
kers, we deﬁned as HPV-driven all the samples that were positive
for HPV DNA and 2 additional HPV-transformation related
markers.
Among the 19 cases with HPV DNA positive tumors evaluated
by this algorithm, 15 (79%) were deﬁned as HPV-driven, conﬁrm-
ing that HPV is not a causal pathogenic factor in all HPV DNA
positive HNSCC [10,12].
Considering the whole HNSCC cohort, we could not see a better
survival in the HPV-driven group, probably due to the low number
of HPV-driven cases that might inﬂuence the statistical power.
Nonetheless, survival analyses restricted to patients with OPSCC
showed a trend of better survival for patients with HPV-driven
tumors.
Due to the low number of tumors from the oropharyngeal site,
the analyses of a multivariate Cox regression and HPV prevalence
over time in the Italian northern region could not be performed.
The results of our study conﬁrm the low prevalence of HPV-
driven HNSCC in North-East-Italy, in line with data from neigh-
boring countries (like Spain), with a signiﬁcant role of HPV16 only
in the oropharynx. Moreover, we highlight the importance of good
classiﬁcation of the truly HPV-driven tumors. Although the addi-
tional markers could not be analyzed in all HNSCC patients (re-
presenting a limitation of the study), the correlations are strong
and point to the use of an algorithm to correctly identify the truly
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